Retension Pharmaceuticals Files Initial Form 3 With SEC Showing Zero Beneficially Owned Securities
Retension Pharmaceuticals, Inc. filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission on October 13, 2026, disclosing that the reporting person beneficially owns zero securities in the company. The filing, designated as SEC Form 3, lists the reporting address at 1104 West Broad Street, Suite 1029, Falls Church, Virginia 22046, according to official regulatory documents.
Filing Details and Sign-Off
The regulatory document indicates that Alex Schwartz signed the initial ownership statement on October 13, 2026. The submission records that no non-derivative or derivative securities are beneficially owned by the reporting person in Retension Pharmaceuticals, which trades under the ticker symbol RTSN with a foreign trading symbol.
Corporate Focus and Product Pipeline Context
While the regulatory filing lists no active shareholdings for the reporting individual, financial platform data from Investing.com notes that trading in financial instruments carries inherent risks. Insidertrades.com reports that Retension Pharmaceuticals operates as a clinical-stage biopharmaceutical company developing medicines for hypertension and cardiovascular diseases. Its lead product candidate, RTN-001, is a next-generation oral small molecule phosphodiesterase-5 inhibitor designed to target nitric oxide signaling and reduce blood pressure in patients with uncontrolled or resistant hypertension.
Frequently Asked Questions
What date was the Form 3 filed for Retension Pharmaceuticals?
The SEC Form 3 for Retension Pharmaceuticals was filed on October 13, 2026.
Where is the reporting address listed on the SEC filing?
The document lists the address as 1104 West Broad Street, Suite 1029, Falls Church, Virginia 22046.
How many securities are reported as beneficially owned in the filing?
The filing states that no securities are beneficially owned, with Alex Schwartz signing the document on October 13, 2026.
Related reading